Andriulli A, Mangia A, Iacobellis A, Ippolito A, Leandro G, Zeuzem S
Division of Gastroenterology, Casa Sollievo della Sofferenza Hospital, IRCCS, San Giovanni Rotondo, Italy.
Aliment Pharmacol Ther. 2008 Aug 15;28(4):397-404. doi: 10.1111/j.1365-2036.2008.03763.x. Epub 2008 Jun 11.
Anti-viral therapy seems more successful in HCV genotype 2 than genotype 3-infected patients.
To report sustained virological response (SVR) rates for HCV-2 and HCV-3 infection.
Meta-analyses were carried out on SVR data on 2275 patients treated for 24 weeks in eight individual trials and on 968 patients with rapid virological response (RVR) treated for 12-16 weeks or 24 weeks in four studies.
After 24 weeks of therapy, SVR rates were 74% and 68%, respectively, for HCV-2 and HCV-3 genotype patients. Among high viraemics, SVR rate in HCV-2 infection (75%) differed from the 58% value in HCV-3 infection. Among low viraemic patients, respective rates were 79% and 75%. In RVR patients treated for 12-16 or 24 weeks, SVR rates in HCV-2 infection were 83% and 84%, respectively, and in HCV-3 infection 84% and 86%. In patients without RVR treated for 24 weeks, SVR was higher in HCV-2, with a 17.8% weighted difference.
Twenty-four weeks of therapy should remain standard duration for HCV-2 and low viraemic HCV-3 patients. In RVR patients, HCV-3 patients respond to short-treatment as well as HCV-2 patients, irrespective of basal viraemia. Patients without RVR may need longer treatment than the recommended 24 weeks.
抗病毒治疗在丙型肝炎病毒（HCV）2型感染患者中似乎比3型感染患者更成功。
报告HCV-2和HCV-3感染的持续病毒学应答（SVR）率。
对八项独立试验中接受24周治疗的2275例患者以及四项研究中接受12 - 16周或24周治疗的968例具有快速病毒学应答（RVR）的患者的SVR数据进行荟萃分析。
治疗24周后，HCV-2和HCV-3基因型患者的SVR率分别为74%和68%。在高病毒血症患者中，HCV-2感染的SVR率（75%）与HCV-3感染的58%不同。在低病毒血症患者中，相应的比率分别为79%和75%。在接受12 - 16周或24周治疗的RVR患者中，HCV-2感染的SVR率分别为83%和84%，HCV-3感染为84%和86%。在未出现RVR且接受24周治疗的患者中，HCV-2的SVR更高，加权差异为17.8%。
24周治疗应仍是HCV-2和低病毒血症HCV-3患者的标准疗程。在RVR患者中，HCV-3患者对短疗程治疗的反应与HCV-2患者相同，无论基础病毒血症如何。未出现RVR的患者可能需要比推荐的24周更长的治疗时间。
